In summary, our findings identify human CIDEC as a potential ‘drug’ or a ‘druggable’ target to reverse obesity-induced lipotoxicity and glucose intolerance. This evidence concerns the gene CIDEC and obesity due to melanocortin 4 receptor deficiency.